LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology
Phase of Trial: Phase I/II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LUME-Lung-3
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 06 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov.